Monday, July 22, 2013
The BioCentury 100 index is
approaching its all-time high set at the peak of the hype-driven genomics
bubble, thanks in large part to large cap performance.
The industry's resurgence has more
fundamental underpinnings this time around. Nevertheless, one technical analyst
thinks some big names might be ripe for near-term profit taking. But he thinks
mid-caps could be poised for growth.